FMP
Leap Therapeutics, Inc.
LPTX
NASDAQ
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
2.46 USD
-0.09 (-3.66%)
Mr. Douglas E. Onsi J.D.
Healthcare
Biotechnology
NASDAQ
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
0001509745
US52187K2006
52187K101
47 Thorndike Street
617 714 0360
US
54
Jan 25, 2017
Dr. Jason S. Baum Ph.D.
Chief Scientific Officer
0
1979
Mr. Augustine J. Lawlor
Chief Operating Officer
749.81k
1957
Mr. Douglas E. Onsi J.D.
Chief Financial Officer, General Counsel...
1.1M
1969
Dr. Cynthia A. Sirard M.D.
Chief Medical Officer
747.57k
1970
Mr. Mark O'Mahony
Chief Manufacturing Officer
0
1971
Ms. Christine M. Granfield
Vice President and Head of Regulatory Af...
0
1968
As of December 31, 2024, the total employee count stands at 54, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.